What is HC Wainwright’s Forecast for BBIO FY2027 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities researchers at HC Wainwright issued their FY2027 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Monday, March 9th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of $1.83 per share for the year. HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million for the quarter, compared to the consensus estimate of $150.71 million. During the same quarter last year, the firm posted ($1.40) EPS. The company’s revenue for the quarter was up 2521.2% compared to the same quarter last year.

Other analysts also recently issued reports about the stock. Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the company an “outperform” rating in a research report on Thursday, February 12th. Truist Financial increased their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company raised their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Leerink Partners boosted their price objective on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $82.50.

BridgeBio Pharma Price Performance

BBIO opened at $65.64 on Tuesday. The company has a 50 day simple moving average of $73.44 and a two-hundred day simple moving average of $65.56. The firm has a market cap of $12.72 billion, a P/E ratio of -17.37 and a beta of 1.13. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94.

Insiders Place Their Bets

In other news, Director Andrea Ellis sold 64,921 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the transaction, the director owned 18,589 shares of the company’s stock, valued at approximately $1,205,868.43. This represents a 77.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Maricel Apuli sold 510 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the transaction, the chief accounting officer owned 123,945 shares in the company, valued at approximately $9,210,352.95. This represents a 0.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 227,095 shares of company stock worth $16,099,240. 18.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently modified their holdings of the business. Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma during the first quarter valued at approximately $35,000. Envestnet Asset Management Inc. lifted its holdings in BridgeBio Pharma by 204.1% during the second quarter. Envestnet Asset Management Inc. now owns 39,487 shares of the company’s stock worth $1,705,000 after buying an additional 26,500 shares during the period. Bank of Montreal Can lifted its holdings in BridgeBio Pharma by 6.0% during the second quarter. Bank of Montreal Can now owns 9,865 shares of the company’s stock worth $426,000 after buying an additional 556 shares during the period. Savant Capital LLC bought a new stake in BridgeBio Pharma during the 2nd quarter valued at $218,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $693,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.